Investigative Landscape in Advanced Non-Melanoma Skin Cancers.
Curr Treat Options Oncol
; 22(7): 56, 2021 06 07.
Article
em En
| MEDLINE
| ID: mdl-34097150
ABSTRACT
OPINION STATEMENT Advanced non-melanoma skin cancers have been challenging to treat due to limited treatment options. Treatment paradigm has shifted with the approval of immunotherapeutic agents cemiplimab and pembrolizumab which have been a key development and have changed the landscape of advanced or metastatic squamous cell skin cancers. Hedgehog inhibitors, vismodegib and sonidegib, remain upfront options for advanced or metastatic basal cell carcinomas. Current clinical trials are continuing to evaluate the use of immune checkpoint inhibitors and hedgehog pathway inhibitors. There is further need for ongoing research and development of new therapies in both malignancies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Carcinoma Basocelular
/
Carcinoma de Células Escamosas
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article